PNC Financial Services Group Inc. held its stake in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 111,436 shares of the biotechnology company’s stock at the end of the second quarter. PNC Financial Services Group Inc. owned approximately 0.08% of ZIOPHARM Oncology worth $693,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Amalgamated Bank increased its position in ZIOPHARM Oncology by 12.9% during the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,924 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in ZIOPHARM Oncology by 50.0% during the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after buying an additional 6,000 shares during the last quarter. BB&T Securities LLC acquired a new position in ZIOPHARM Oncology during the second quarter worth approximately $112,000. Principal Financial Group Inc. increased its position in ZIOPHARM Oncology by 7.5% during the second quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after buying an additional 1,673 shares during the last quarter. Finally, Ballentine Partners LLC acquired a new position in ZIOPHARM Oncology during the second quarter worth approximately $162,000. 41.94% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have weighed in on ZIOP shares. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. BidaskClub downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Finally, HC Wainwright set a $10.00 price target on ZIOPHARM Oncology and gave the stock a “buy” rating in a research report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. ZIOPHARM Oncology has a consensus rating of “Hold” and a consensus target price of $16.50.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. During the same period in the prior year, the business earned ($1.01) EPS. ZIOPHARM Oncology’s quarterly revenue was down 5.9% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/pnc-financial-services-group-inc-continues-to-hold-stake-in-ziopharm-oncology-inc-ziop/1627418.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.